Literature DB >> 779423

Pharmacological principles of brain tumor chemotherapy.

V A Levin.   

Abstract

In conclusion, I would like to reiterate the belief that curative therapy will require both CCNS cytocidal drugs and appropriately timed CCS agents. Lipophilic drugs will remain our most valuable drugs unless new agents appear that have very high therapeutic indices and can be given by prolonged or intermittent infusion. The lipophilic drugs have the advantages of greater penetrability of tumor cells and preferential partitioning in lipid membranes and cellular structures. Potentially, combinations of differently acting CCNS agents should maximize DNA damage and prevent DNA repair. Infusions of CCS drugs for 3 to 4 days, following an interval of 6 to 14 days after the administration of CCNS agents, should result in maximum damage to proliferating tumor cells, preventing cell division for 1 week and contributing another 1 log cell kill to the therapy.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 779423

Source DB:  PubMed          Journal:  Adv Neurol        ISSN: 0091-3952


  5 in total

1.  The VM model of glioma: preparation of multicellular tumour spheroids (MTS) and their response to chemotherapy.

Authors:  R Bradford; J L Darling; N Sier; D G Thomas
Journal:  J Neurooncol       Date:  1990-10       Impact factor: 4.130

Review 2.  Drug or vaccine?: selecting the appropriate treatment for malignant glioma patients.

Authors:  Xue-jun Dai; Wei-jian Jiang; Wei-min Wang; Shu-jin Zhao
Journal:  Drugs       Date:  2010-08-20       Impact factor: 9.546

3.  Understanding brain penetrance of anticancer drugs.

Authors:  Victor A Levin; Benjamin M Ellingson
Journal:  Neuro Oncol       Date:  2018-04-09       Impact factor: 12.300

Review 4.  Recent progress towards development of effective systemic chemotherapy for the treatment of malignant brain tumors.

Authors:  Hemant Sarin
Journal:  J Transl Med       Date:  2009-09-01       Impact factor: 5.531

5.  Impact of phase II trials with progression-free survival as end-points on survival-based phase III studies in patients with anaplastic gliomas.

Authors:  Victor A Levin; Sandra Ictech; Kenneth R Hess
Journal:  BMC Cancer       Date:  2007-06-22       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.